Verbesserte Therapiekonzepte beim Magenkarzinom

Zusammenfassung

Beim Magenkarzinom sind die Therapiemöglichkeit limitiert, vor allem im fortgeschrittenen Stadium. Priv.-Doz. Dr. Sylvie Lorenzen, Klinikum rechts der Isar, München, sprach auf dem Deutschen Krebskongress über Verbesserungen der Prognose von Magenkarzinompatienten durch zielgerichtete Therapien.

 

• Literatur

• 1 Janjigian YY. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer.. Cancer Discov 2018; 8: 49-58
• 2 Tabernero J. et al. Pertuzumab + trastuzumab + chemotherapy for HER2-positive metastastic gastric or gastro-oesophageal junction cancer: Final analysis of a phase III study (JACOB).. Ann Oncol 2017; 28 Suppl (Suppl. 05) Abstract 616O
• 3 Wilke H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A doubleblind, randomised phase 3 trial. Lancet Oncology. 2014
• 4 Fuchs CS. et al. RAINFALL: A randomized, doubleblind, placebo-controlled phase III study of cisplatin plus capecitabine or 5FU with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. ASCO GI. 2018. Abstract
• 5 Fuchs CS. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial.. JAMA Oncol. 2018; 4 (05) e180013 doi:10.1001/jamaoncol.2018.0013 Published online March 15, 2018
• 6 Kang YK. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cacner refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet 2017; 390: 2461-2471
• 7 Ott P. et al. Nivolumab in patients with advanced chemotherapy-refractory esophagogastric cancer according to microsatellite instability status: CheckMate 032. ESMO. 2017. Abstract 674P
• 8 Bang YJ. et al. Interim safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma from a multicohort phase I study of ramucirumab plus durvalumab. ASCO GI. 2018. Abstract 92
• 9 Chau I. et al. Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction adenocarcinoma: Preliminary results from a multi-disease phase I study.. J Clin Oncol 2018; 36 Suppl (Suppl. 04) S Abstract 101